Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.50 |
| ▸ | KIF11 | P52732 | 12/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CHUK | O15111 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2932286 | 0.84 | KCNMA1 (0.47) | KCNMA1KIF11CDK4CCND1CCNB2 | |
| SCHEMBL2934874 | 0.81 | KCNMA1 (0.50) | KCNMA1KIF11CDK4CCND1 | |
| SCHEMBL2932491 | 0.78 | KCNMA1 (0.50) | KCNMA1KIF11CDK4CCND1 | |
| SCHEMBL2930924 | 0.77 | KCNMA1 (0.49) | KCNMA1KIF11KDM4EMEN1KMT2A | |
| SCHEMBL2925140 | 0.77 | KCNMA1 (0.61) | KCNMA1KIF11MEN1KMT2A | |
| SCHEMBL2931881 | 0.77 | KCNMA1 (0.57) | KCNMA1KIF11CDK4CCND1 | |
| SCHEMBL2932784 | 0.76 | KCNMA1 (0.57) | KCNMA1KIF11CDK4CCND1 | |
| SCHEMBL13564564 | 0.75 | PIM1 (0.45) | KCNMA1KIF11KDM4E | |
| SCHEMBL2925491 | 0.73 | KCNMA1 (0.68) | KCNMA1KDM4EMEN1KMT2A | |
| SCHEMBL2930598 | 0.73 | KCNMA1 (0.46) | KCNMA1KIF11KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812177-B2 | Potassium channel opener having benzofuroindole skeleton | ANYGEN CO., LTD. (KR) | 2010-10-12 | — | — | US | disclosed |
| EP-1861092-B1 | POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON | ANYGEN CO LTD (KR) | 2010-09-15 | — | — | EP | disclosed |
| EP-1861092-A4 | POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON | ANYGEN CO LTD (KR) | 2009-04-15 | — | — | EP | disclosed |
| US-20080194837-A1 | Potassium Channel Opener Having Benzofuroindole Skeleton | ANYGEN CO., LTD. (KR) | 2008-08-14 | — | — | US | disclosed |
| EP-1861092-A1 | POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON | Anygen Co., Ltd. (KR) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006096030-A1 | POTASSIUM CHANNEL OPENER HAVING BENZOFUROINDOLE SKELETON | ANYGEN CO., LTD. (KR) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194837-A1 | Potassium Channel Opener Having Benzofuroindole Skeleton | KCNJ2, KCNN3, KCNH2 | KCNMA1 41/4885KIF11 636/4885KDM4E 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.